IL321783A - Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds - Google Patents
Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compoundsInfo
- Publication number
- IL321783A IL321783A IL321783A IL32178325A IL321783A IL 321783 A IL321783 A IL 321783A IL 321783 A IL321783 A IL 321783A IL 32178325 A IL32178325 A IL 32178325A IL 321783 A IL321783 A IL 321783A
- Authority
- IL
- Israel
- Prior art keywords
- chemical
- crystalline forms
- nlrp3 inflammasome
- inflammasome inhibitors
- chemical compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
- C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263477516P | 2022-12-28 | 2022-12-28 | |
| PCT/EP2023/087813 WO2024141534A1 (en) | 2022-12-28 | 2023-12-27 | Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321783A true IL321783A (en) | 2025-08-01 |
Family
ID=89619412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321783A IL321783A (en) | 2022-12-28 | 2023-12-27 | Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4642763A1 (en) |
| JP (1) | JP2026502218A (en) |
| KR (1) | KR20250162767A (en) |
| CN (1) | CN120435457A (en) |
| AU (1) | AU2023417850A1 (en) |
| CL (1) | CL2025001938A1 (en) |
| IL (1) | IL321783A (en) |
| MX (1) | MX2025007667A (en) |
| WO (1) | WO2024141534A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250074627A (en) * | 2023-11-20 | 2025-05-27 | 벤투스 테라퓨틱스 유에스 인코포레이티드 | SOLID FREEBASE FORMS OF 5-chloro-2-(4-((2-hydroxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-yl)phenol FOR INHIBITING NLRP3 AND USES THEREOF |
| TW202545527A (en) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3 and glp-1a combination therapies |
| CN120904042B (en) * | 2025-07-22 | 2026-05-01 | 安徽医科大学 | Azafeone derivative with liver ischemia reperfusion injury resisting activity, and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119731A1 (en) | 2019-05-17 | 2022-01-05 | Novartis Ag | NLRP3 INFLAMASOME INHIBITORS |
| TW202231281A (en) | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | A class of pyridazine containing compounds and medicinal uses thereof |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| PL4363406T3 (en) * | 2021-07-02 | 2026-01-05 | Astrazeneca Ab | NLRP3 INFLAMASOME INHIBITORS |
-
2023
- 2023-12-27 KR KR1020257025335A patent/KR20250162767A/en active Pending
- 2023-12-27 AU AU2023417850A patent/AU2023417850A1/en active Pending
- 2023-12-27 EP EP23841209.2A patent/EP4642763A1/en active Pending
- 2023-12-27 WO PCT/EP2023/087813 patent/WO2024141534A1/en not_active Ceased
- 2023-12-27 JP JP2025538042A patent/JP2026502218A/en active Pending
- 2023-12-27 IL IL321783A patent/IL321783A/en unknown
- 2023-12-27 CN CN202380089487.2A patent/CN120435457A/en active Pending
-
2025
- 2025-06-27 CL CL2025001938A patent/CL2025001938A1/en unknown
- 2025-06-27 MX MX2025007667A patent/MX2025007667A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025007667A (en) | 2025-12-01 |
| AU2023417850A1 (en) | 2025-08-14 |
| KR20250162767A (en) | 2025-11-19 |
| WO2024141534A1 (en) | 2024-07-04 |
| CN120435457A (en) | 2025-08-05 |
| JP2026502218A (en) | 2026-01-21 |
| EP4642763A1 (en) | 2025-11-05 |
| CL2025001938A1 (en) | 2026-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL318258A (en) | Novel nlrp3 inflammasome inhibitors | |
| SI4363406T1 (en) | Nlrp3 inflammasome inhibitors | |
| IL306022A (en) | Inhibitors of nlrp3 inflammasome | |
| IL318533A (en) | Nlrp3 inflammasome inhibitors | |
| IL307188A (en) | Nlrp3 inhibitors | |
| AU2023414924A1 (en) | Heterocyclic and heteroaryl compounds as inhibitors of nlrp3 | |
| EP4349827A4 (en) | Acid salt of crystalline csf-1r inhibitor, and preparation method therefor and use thereof | |
| IL315457A (en) | Solid forms, salts, and processes of preparation of a cdk2 inhibitor | |
| AU2024255473A1 (en) | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 | |
| MX2025007667A (en) | Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds | |
| IL319011A (en) | Triazinone derivatives as nlrp3 inhibitors | |
| IL319009A (en) | Triazinone derivatives as nlrp3 inhibitors | |
| AU2024240240A1 (en) | Urea derivatives for inhibiting nlrp3 and uses thereof | |
| CA3278581A1 (en) | Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds | |
| AU2024238394A1 (en) | Amide derivatives for inhibiting nlrp3 and uses thereof | |
| HK40099180A (en) | Inhibitors of nlrp3 inflammasome | |
| HK40117000A (en) | N-oxide inhibitors of nlrp3 inflammasome | |
| TWI926416B (en) | Inhibitor compounds for selective passivation of surfaces | |
| PT4337652T (en) | Nlrp3 inhibitors | |
| HK40122493A (en) | Nlrp3 inflammasome inhibitors | |
| CA3280638A1 (en) | Inhibitors of nlrp3 | |
| HK40128873A (en) | Novel nlrp3 inflammasome inhibitors | |
| HK40109676A (en) | Inhibitors of nlrp3 | |
| CA3277202A1 (en) | Heterocyclic and heteroaryl compounds as inhibitors of nlrp3 | |
| HK40129405A (en) | Indazole and pyrazolopyridine compounds as inhibitors of nlrp3 inflammasome |